Immutep Announces First Clinical Data from 90mg Dosing of Efti

 

• Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well tolerated
• Encouraging initial efficacy in six metastatic breast cancer patients, who exhausted all endocrine therapy including CDK4/6 inhibitors, demonstrated by a 50% overall response rate, including one complete response, and a 100% disease control rate

https://www.biospace.com/article/releases/immutep-announces-first-clinical-data-from-90mg-dosing-of-efti/